financetom
Business
financetom
/
Business
/
Standard Nuclear reveals revenue rise in US IPO filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Standard Nuclear reveals revenue rise in US IPO filing
Jun 18, 2026 3:51 PM

* Quarterly revenue increases to $593,802

* Company plans NYSE listing as 'STDN'

* Earlier funding round raised $140 million

(Adds details on nuclear firms' IPOs)

June 18 (Reuters) - Nuclear fuel company Standard Nuclear

reported an increase in quarterly revenue as it filed for an

initial public offering in the United States on Thursday,

joining a host of startups looking to tap the public markets.

Activity in the U.S. IPO market has seen a rebound in recent

months, with several sectors joining in on the investor

enthusiasm surrounding fresh stocks currently prevailing.

President Donald Trump signed executive orders in May 2025,

aimed at jumpstarting the U.S. nuclear energy industry by easing

the regulatory process on approvals for new reactors and

strengthening fuel supply chains.

Nuclear reactor developer X-Energy ( XE ) debuted in New

York in April after raising $1.02 billion in its IPO while Deep

Fission went public earlier in the day.

Standard Nuclear produces advanced nuclear fuel and

radioisotope power systems, with a focus on scaling up domestic

manufacturing capacity to bolster U.S. energy security.

It is the only independent producer in the United States of

TRISO fuel - a high-performance material used in next-generation

nuclear reactors - according to the IPO filing.

The company supplies reactor-agnostic fuel solutions for

both terrestrial and space applications, serving aerospace and

defense customers.

Standard Nuclear announced earlier this year that it had

raised $140 million in an early-stage funding round led by

Decisive Point. Its other backers include Chevron Technology

Ventures and Andreessen Horowitz.

The company reported revenue of $593,802 in the three months

ended March 31, compared with $377,926 a year earlier.

The terms of the offering were not disclosed in the filing.

It said the proceeds from the IPO would go towards general

corporate purposes and to acquire or invest in complementary

businesses.

The company intends to list its shares on the New York Stock

Exchange under the ticker symbol "STDN". BofA Securities,

Goldman Sachs, Barclays and UBS Investment Bank are among the

underwriters for the offering.

(Reporting by Pritam Biswas in Bengaluru; Editing by Joyjeet

Das)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Day One Biopharmaceuticals Q3 revenue beats estimates on OJEMDA strength
Day One Biopharmaceuticals Q3 revenue beats estimates on OJEMDA strength
Nov 4, 2025
Overview * Day One Q3 revenue of $39.8 mln beats analyst expectations * OJEMDA net product revenue rises 15% from Q2, driven by higher patient demand * Company raises full-year 2025 OJEMDA revenue guidance to $145-$150 mln Outlook * Company raises OJEMDA full-year 2025 revenue guidance to $145-$150 mln Result Drivers * INCREASED DEMAND - OJEMDA net product revenue rose...
Soleno Therapeutics posts Q3 profit on strong VYKAT XR sales 
Soleno Therapeutics posts Q3 profit on strong VYKAT XR sales 
Nov 4, 2025
Overview * Soleno Q3 net income at $26 mln, achieving profitability with VYKAT XR sales * VYKAT XR sales reach $66 mln in Q3, more than doubling from previous quarter * Company raised $230 mln through stock offering, strengthening financial position Outlook * Soleno expects selling, general and administrative expenses to rise post-VYKAT XR commercialization Result Drivers * VYKAT XR...
Tech firm Mercury Systems Q1 profit beats expectations on strong demand 
Tech firm Mercury Systems Q1 profit beats expectations on strong demand 
Nov 4, 2025
Overview * Mercury Systems ( MRCY ) fiscal Q1 rev grows 10.2% yr/yr, beating analyst expectations * Adjusted EPS for fiscal Q1 beats consensus, improving significantly year-over-year * Company announced $200 mln share repurchase program, reflecting confidence in future prospects Outlook * Mercury Systems ( MRCY ) did not provide specific future revenue or EPS guidance in the statement Result...
Mirum Pharmaceuticals Q3 revenue rises on LIVMARLI sales growth
Mirum Pharmaceuticals Q3 revenue rises on LIVMARLI sales growth
Nov 4, 2025
Overview * Mirum Pharmaceuticals Q3 2025 revenue rises 47% yr/yr to $133 mln * Net income for Q3 2025 at $2.9 mln, a turnaround from loss last year * Mirum updates 2025 revenue guidance to $500-$510 mln Outlook * Mirum updates 2025 revenue guidance to $500-$510 mln * Company expects VISTAS study topline data in Q2 2026 * Mirum anticipates...
Copyright 2023-2026 - www.financetom.com All Rights Reserved